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(wileyoAbstract—Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, are among the many pharmaceuticals detected in aquatic
ecosystems. Although the acute effects of SSRIs on select organisms have been reported, little is understood about the chronic effects of
these drugs on amphibians, which are particularly sensitive to environmental pollutants. Serotonin plays important roles in many
physiological functions, including a wide array of developmental processes. Exposure to SSRIs during development may cause
developmental complications in a variety of organisms, but little is known about the degree of exposure necessary to cause deleterious
effects. Here, we sought to gain a better understanding of the effects of SSRIs on amphibian development by use of a combined
laboratory and outdoor mesocosm study. Tadpoles in a laboratory setting were exposed to a low (0.029mg/L) and a high (0.29mg/L)
concentration of the common SSRI fluoxetine from stages 21 and 22 through completion of metamorphosis. Tadpoles in outdoor
mesocosms were exposed to fluoxetine concentrations ranging from 0.1 to 0.3mg/L. Exposed tadpoles in the laboratory showed delayed
development compared with controls when stage was assessed throughout the experiment. Control tadpoles also gained weight faster
than treatment tadpoles, which may be explained by reduced food intake. Mesocosm tadpoles exhibited similar trends, but no significant
differences were detected. These results indicate that ecologically relevant levels of fluoxetine may cause developmental delays in
amphibians. Environ. Toxicol. Chem. 2010;29:2845–2850. # 2010 SETACKeywords—Pharmaceuticals Toxicity Selective serotonin reuptake inhibitor Amphibian EnvironmentINTRODUCTION
Trace quantities of human and veterinary pharmaceuticals
have been detected in diverse water sources, such as surface
waters, groundwater, seawater, and even drinking water [1–3].
Most human pharmaceuticals enter such aquatic systems
through wastewater treatment plants (WWTPs) primarily due
to human defecation of pharmaceuticals and their metabolites
after use [4,5]. Although measured concentrations of these
chemicals in receiving waters are small (i.e., sub part per
billion) [5], growing evidence indicates that such low levels
may be affecting aquatic organisms, that synergistic interac-
tions occur, and that levels are increasing [4]. Accordingly,
pharmaceuticals in waterways are considered a class of environ-
mental contaminant of global importance [1]. Given that a
majority of ecotoxicological studies on pharmaceuticals have
focused on their acute toxicity [1,6], little is known about their
impacts on organisms and ecosystems after chronic exposures
to real-world levels [1,6].
Selective serotonin reuptake inhibitors (SSRIs) are among
the most commonly prescribed drugs in the United States, with
fluoxetine and sertraline in the top 20 most frequently pre-
scribed drugs in 2007 (http://drugtopics.modernmedicine.com/
drugtopics/Top200Drugs/ArticleStandard/article/detail/491194).
At least four drugs of this class and their active metabolites
have been detected in WWTP raw wastewater at individual
levels as high as 0.223mg/L [2,3,7,8]. Fluoxetine has beeno whom correspondence may be addressed
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2845found in sewage treatment plant effluents and surface waters at
concentrations as high as 0.099mg/L [9]. In addition, evidence has
been noted of bioaccumulation, since fluoxetine, citalopram,
sertraline, and their metabolites have been measured in the tissues
of fish living in effluent-dominated streams [3,10].
In humans, SSRIs are used primarily to treat chronic depres-
sion and compulsive disorders by blocking the reuptake of
serotonin from the presynaptic nerve cleft [6]. Serotonin is
conserved across organisms, and in addition to its neurochem-
ical role, with subsequent effects on mood and behavior [11], it
mediates many other physiological processes in every class of
organisms [12–14]. For example, serotonin plays a crucial role
in immune function, steroid concentrations, and sexual func-
tion. Serotonin is also critical during key developmental proc-
esses in every organism studied thus far [6,13–15], and
exposure to SSRIs during development is believed to cause
deformities or other developmental complications in a wide
array of organisms, including sea urchins, birds, mice, and even
humans [13,14,16–18]. However, little is known about the dose
and duration of exposure necessary to cause deleterious effects
in developing embryos and whether such early-life exposures
result in later-life effects.
Many aquatic organisms are currently threatened or endan-
gered, but recent drastic declines in amphibian populations have
led to great concern for their preservation, and research has
shown that amphibians may be particularly susceptible to
environmental stressors. Most amphibians live in water
throughout their egg and larval stages, making them excep-
tionally vulnerable to aquatic contaminants during this critical
time of development. Furthermore, their shell-less eggs and
permeable skin easily allow the absorption of substances found
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be a contributor to global amphibian declines [20]. Although
pharmaceuticals may not be a major contributor to amphibian
declines because pharmaceutical contamination is limited to
aquatic ecosystems near WWTPs [1], a better understanding
of these contaminants still may aid in the effort to preserve
amphibians as human populations, pharmaceutical use, and the
prevalence of WWTPs increase worldwide.
In the present study, we sought to gain a more complete
understanding of the effects of SSRIs on amphibian develop-
ment after chronic exposures to relevant levels. To accomplish
this, frogs (Rana pipiens) were exposed to low levels of SSRIs
from stages 21 to 22 until the completion of metamorphosis
both in the laboratory and in a mesocosm study. Because
serotonin is critical to vertebrate craniofacial development,
and changes in serotonin levels in developing embryos have
been linked to skeletal deformities, we hypothesized that frogs
raised in water with low levels of fluoxetine will exhibit an
increase in developmental malformations. In addition, serotonin
is thought to influence cell proliferation, as well as appetite and
other behaviors, so we also expected to observe developmental
delays and behavioral abnormalities.
METHODS
Collection of frogs
All procedures were approved by the University Committee
for the Use and Care of Animals at the University of Michigan.
For both the laboratory and mesocosm study, a total of approx-
imately 1,500 Rana pipiens stage 21 and 22 larvae (according to
the Gosner staging system, which assigns a stage, 1 to 46, to frog
larvae from egg to completion of metamorphosis, based on
morphological developments [21]; heretofore stage) were col-
lected from a small vernal pond in Livingston County, Mich-
igan, USA, from at least two different egg masses on May 1,
2009. Although the history of contamination of this pond is
unknown, it is likely not contaminated by pharmaceuticals
because it is not in the vicinity of a WWTP.
Chemical
Fluoxetine hydrochloride (Toronto Research Chemicals)
was dissolved in dechlorinated city water to achieve a stock
solutions of 1 mg/L. Stock solutions were refrigerated at 58C
and renewed every two to three weeks. The resulting concen-
tration of fluoxetine in each treatment tank was verified by the
Worsfold Water Quality Centre (Trent University, Peterbor-
ough, ON, Canada), using liquid chromatography-mass spec-
trometry as described in a previous article [22]. For this
analysis, nine grab samples were taken from the laboratory
and mesocosm experiments on August 10, 2009. Samples were
taken from the laboratory experiments as follows: a composite
of the three control tubs after water changing, one composite of
the three high treatment tubs before and one after water
changing, and one sample from each of the three low treatment
tubs after water changing. For the mesocosm experiments, a
composite of control water and a composite of the treated water
before and after the spike were taken.
Laboratory experiment
Housing and care. Nine plastic 5.7-L Sterilite1 plastic
boxes were filled with 4 L of dechlorinated city water
(pH 7.05). Boxes were kept at 238C on a 16:8 light:dark
schedule. To each box, 20 stage 21 to 22 tadpoles were
arbitrarily added on May 8, 2010 (day 0). Tadpoles were fedan ad libitum diet of rabbit chow and TetraMin1 tropical fish
flakes in a 10:1 ratio every 2 to 3 d. Boxes were randomly
selected to contain water with no fluoxetine (control), a low,
environmentally relevant treatment (<0.1mg/L), and a high
treatment (<1.0mg/L), resulting in three replicates for each
treatment and 20 tadpoles per replicate. Water was changed
(100% static renewal) every 3 to 4 d.
Monitoring stage and weight. The stage of each individual
tadpole was assessed and recorded on day 33, day 40, and day
50. Weight was recorded on 20 different days from day 5 until
day 45 by weighing the tadpoles of each tub collectively to
obtain an average weight. We stopped weighing the animals
collectively on day 45 because some of the tadpoles were
beginning to metamorphose, at which point tadpoles lose
weight until completion of metamorphosis. When forelimbs
were nearly fully developed and tail resorption was beginning,
the tadpole was removed from its box and placed in a slightly
sloped container containing 100 ml water with, depending on
the original treatment to which the tadpole belonged, no fluox-
etine or the high or low concentration of fluoxetine. All tadpoles
from the same treatment were housed together once they
reached forelimb bud development, but at no point did the
number of tadpoles in the sloped boxes exceed 5, and we kept
track of the replicates from which each of the tadpoles came.
The progress of each tadpole was tracked from forelimb bud
development until the completion of metamorphosis or death.
On completion of metamorphosis (complete tail resorption) or
death, the date was recorded. Tadpole weight was recorded
when a tadpole completed metamorphosis. Metamorphosed
individuals were anesthetized by using tricaine methanesulfo-
nate and killed by quick-freezing on dry ice.
Swimming ability test. On day 42, 12 tadpoles from each
treatment were randomly selected to participate in a swimming
speed assessment (to control for weight and stage, however,
selection was limited to tadpoles between the stages of 25 and
31) based on methods previously described by Chen et al. [23].
A 1-m racetrack was created out of plastic gutter material. A
tadpole was placed in a 6-cm section blocked off by a piece of
plastic in front of the start of the 1-m track and was allowed
to acclimate for 30 s. At this point, the plastic was lifted. To
achieve maximum swimming speed, the tadpole was chased
down the track with a thin strip of plastic (1 cm in width). The
person chasing the tadpoles was blind to the treatment from
which each tadpole came. The time it took for a tadpole to reach
the end of the 1-m track, while being chased, was recorded and
converted to speed in centimeters per second. Each tadpole was
tested only once.
Feeding time. Individual tadpoles (12 randomly chosen per
treatment group) were monitored on day 25 for differences in
time spent feeding. Because tracking a single tadpole in its tub
with many other tadpoles is quite difficult, a tadpole was placed
in a separate 250-ml beaker of water with a fresh pellet of rabbit
chow and allowed to acclimate for 5 min. Time spent feeding
during the next 5 min was recorded.
Mesocosm experiment
To evaluate whether fluoxetine would similarly affect tad-
poles raised in a more natural setting, we also set up a mesocosm
experiment with a control and an exposed group on May 1, 2010
(Day 0-M; ‘‘M’’ denotes mesocosm). Tadpoles (30 per tub)
were housed in eight 64-L plastic storage bins filled with pond
water and sediment in the Saginaw Forest Preserve (Ann Arbor,
MI, USA). Algae was collected from the local pond and added
to the tubs as food for the tadpoles. Four of the tubs were treated
Fig. 1. Mean stage (standard error) of tadpoles on day 33, day 40, and
day 50 (n¼ 3 per treatment group per day). Capital letters denote significant
differences (p< 0.05).
Fig. 2. Mean weight (standard error) of tadpoles on 20 d between day 5 and
day 45 (n¼ 3 per treatment group per day). Capital letters denote significant
differences (p< 0.05).
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Because previous studies had reported adsorption of fluoxetine
into the soil in outdoor water systems [24], treated tubs were
spiked twice per week with 0.05 g fluoxetine, thus resulting in a
nominal concentration of less than 1mg/L. Tubs were covered
with screen to avoid invasion by predators and monitored every
3 to 4 d. On day 123-M, as the first of the tadpoles were
developing forelimbs, the weight and stage of each tadpole was
recorded.
Statistical analysis
For the laboratory study, a repeated measures analysis of
variance was used to assess differences in weight among treat-
ments over the course of 20 d from day 5 until day 45, and
a Friedman test was used to determine differences in stage
among treatments on day 33, day 40, and day 50. Because
post-hoc comparisons are not possible for nonparametric tests, a
Wilcoxon test with Bonferroni adjustments was used to assess
specific differences between individual treatments. Variables
measured only at the termination of the experiment were
examined using one-way analysis of variance when
the assumptions of normality and equal variance (Levene’s
homogeneity of variance) were met. Time to metamorphosis,
weight on completion, and swimming speed met the assump-
tions of analysis of variance, and post-hoc comparisons
were made using Tukey’s honestly significant difference test.
Feeding activity exhibited unequal variances, and treatments
were compared by using a Kruskal-Wallis nonparametric test.
For the mesocosm test, an independent samples t test was
applied to test for significant differences in stage and weight
of tadpoles.
RESULTS
Liquid chromatography–mass spectrometry analysis
In the composite sample of water from the control tubs used
in the laboratory study, a concentration of 0.005mg/L fluoxetine
was measured (limit of quantitation¼ 0.003). The measured
fluoxetine concentration of the low treatment (<0.1mg/L) was
0.029mg/L (0.005mg/L), and the concentration of the com-
posite for the high treatment (<1.0mg/L) was 0.08mg/L before
water changing and 0.29mg/L after water changing. The con-
centration of fluoxetine in the mesocosm experiment control
tubs was less than the limit of quantitation (0.003mg/L),
whereas the fluoxetine concentration measured in the exper-
imental tubs ranged from 0.110 to 0.310mg/L, because of the
spiking of the tubs twice per week.
Laboratory experiment
Survivorship and malformations. No malformations were
observed in any of the tadpoles. No dose-dependent changes
in survivorship were seen among treatments in either the
laboratory experiment or the mesocosm experiment.
Stages, weights, and time to metamorphosis. When stage
was assessed on day 33, day 40, and day 50, control tadpoles
were significantly further developed than both low-
(Z¼2.666; corrected p¼ 0.024) and high-treatment tadpoles
(Z¼2.666; corrected p¼ 0.024; Fig. 1). No difference was
seen in stage between the medium and high fluoxetine–treated
tadpoles.
Results for tadpole weight exhibited a similar trend
( F2,6¼ 11.744, p¼ 0.008; Fig. 2). Tadpoles in the control
group gained weight significantly faster than those in the hightreatment group (p¼ 0.007) and faster than those in the low
treatment groups, although the difference was only marginally
significant in this case (p¼ 0.064). Weight in the control group
had a slope (g/d) 10% greater than that of those exposed to low
concentrations of fluoxetine and 19% greater than high-treat-
ment tadpoles between day 5 and day 45 (Fig. 2). Weight at
forelimb bud development was not significantly different
among treatments ( F2,6¼ 1.772, p¼ 0.267), but the trend
was the same, with control tadpoles weighing approximately
25% more than low- and high-treatment tadpoles, which were
similar in weight. At completion of metamorphosis, treatments
did exhibit nearly significant differences in weight; this time,
however, between high-treatment tadpoles, weighing 0.81 g,
and low-treatment tadpoles, weighing 0.61 grams
( F2,6¼ 4.630; p¼ 0.061; Fig. 3A). No significant differences
were found between the weight of high-treatment tadpoles and
that of control treatment tadpoles (p¼ 0.795).
For time to completion of metamorphosis, although trends
were observed, these were not of statistical significance
( F2,6¼ 1.49, p¼ 0.298). Control tadpoles averaged completion
of metamorphosis in 93 d (12 d), completing metamorphosis
three weeks in advance of low-treatment tadpoles (115 9 d;
Fig. 3. (A) Mean weight (standard error) of tadpoles on completion of
metamorphosis (n¼ 3 per treatment group). (B) Mean time to metamorphosis
(days; standard error) of tadpoles (n¼ 3 per treatment group).
Fig. 5. (A) Mean stage (standard error) of tadpoles in mesocosm
experiment on day 123-M (n¼ 4 per treatment group). (B) Mean weight
(standard error) of tadpoles in mesocosm experiment on day 123-M.
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p¼ 0.418; Fig. 3B).
Behavioral tests
For tests on swimming speed, no fluoxetine-dependent
differences were found. For the feeding test, no significant
differences were observed among treatments. However, a non-
significant trend was observed with control tadpoles spending,
on average, more time feeding than the low- and high-treatment
tadpoles (Fig. 4).
Mesocosm experiment
Although the trends for weight and stage in the mesocosm
experiment were similar to those observed in the laboratory
experiment, surviving control tadpoles on day 123-M were not
significantly further developed nor significantly heavier than
treated animals (Fig. 5).Fig. 4. Mean time spent feeding (standard error) during 5 min of
observation (n¼ 3 per treatment group).DISCUSSION
Aquatic contaminants can have dramatic effects on the
exposed organisms, resulting in deformities, illness, increased
stress, or death, among other things. Although differences in
behavior, malformations, and mortality were not detected, the
results of this study indicate that chronic exposure to environ-
mentally relevant concentrations of the aquatic contaminant
fluoxetine may cause developmental delays and decreased
growth in R. pipiens tadpoles. Retarded growth and develop-
ment can be detrimental to individual amphibians as well as
amphibian populations at large, and in severe cases, may cause
local population declines [25].
Experimental concentrations of fluoxetine for the low treat-
ment were determined to be well within the range of environ-
mentally relevant concentrations (0.012–0.099mg/L) [9],
whereas the concentration of fluoxetine in the high treatment
was approximately three times the highest recorded concen-
tration in the environment. When samples were taken at the end
of the summer, fluoxetine was discovered in water from the
controls at a level of 0.005mg/L. This indicates that there may
have been some contamination in the collection process, or the
control tadpoles may have been exposed to an extremely low
dosage of fluoxetine at some time during the experiment. We do
not believe this exposure influenced the outcome of our experi-
ment because exposure time was probably limited to a short
period, and the measured level approached the analytical limit
of detection.
No significant differences in malformations or overall mor-
tality were observed. These results confirm the findings made
by Conners et al. [26] in Xenopus laevis tadpoles that were
exposed for 70 d to fluoxetine (0.1, 1, 10mg/L). Here, tadpoles
exposed to fluoxetine at both high and low concentrations
exhibited delays in development in laboratory experiments.
Tadpoles in the control group also gained weight faster than
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note, high-treatment tadpoles appeared to lose less weight from
forelimb bud development to completion of metamorphosis,
allowing them to surpass low-treatment tadpoles in weight by
the time they completed metamorphosis. Although the mech-
anism behind this is unclear, Conners et al. [26] found an
acceleration in developmental rate closer to metamorphosis
for tadpoles treated with sertraline, another SSRI. Additionally,
Conners et al. [26] did not observe reduced weight in tadpoles
before metamorphosis, but they did find reduced weight
in tadpoles exposed to higher concentrations of fluoxetine
(10mg/L) on completion of metamorphosis.
In mesocosm experiments, similar trends were observed, but
the differences were not of statistical significance. However,
because of the propensity for variability in outdoor mesocosms
and the small sample size, this is likely attributable to a lack
of statistical power. The combined results from the laboratory
and mesocosm studies suggest that chronic exposures to eco-
logically relevant levels of fluoxetine may delay amphibian
development and impact weight gain.
The observation of fluoxetine-associated delays in develop-
ment and decreased weight may be caused by a number of
factors. Most notably, SSRIs are known anorexigenics [27],
acting at the level of food intake [28], so exposure to fluoxetine
may reduce appetite and, consequently, food intake in tadpoles.
Reduced food intake in turn could result in delayed develop-
ment and reduced weight. Here, food intake was measured in a
subset of animals, and although a trend of control tadpoles
eating more than exposed tadpoles was seen, this was not
statistically significant. Conners et al. [26] observed decreased
food intake in tadpoles treated with fluoxetine as well, coming
to similar conclusions that tadpole exposure to SSRIs may
result in decreased food intake, thereby delaying development.
Further study with increased sample sizes and rigorous and
more regular measures of food intake might elucidate these
results.
Decreased weight in amphibian larvae, as seen in this
experiment, is hypothesized to be deleterious to amphibian
populations for many reasons. Numerous studies have reported
patterns in size-specific predation in larval anurans, with
increased risk of predation for smaller tadpoles [29,30]. This
size-specific predation is observed in part because faster-grow-
ing tadpoles quickly become too large for the gape size of
certain predators [25,31]. Moreover, weight is generally corre-
lated with swimming speed [32,33], so, although no differences
in swimming speed among treatments were found in this study
because we controlled for size, fluoxetine may indirectly impact
swimming speed by decreasing larval size. Therefore, exposed
tadpoles may be less capable of escaping predation because of
decreased swimming speed caused by retarded development.
In the current study, significant differences in time to
metamorphosis among treatments were not detected, but trends
similar to those throughout metamorphosis were observed. We
believe that the nonsignificance of our results in this case is
probably attributable to a lack of statistical power because we
only had three replicates per treatment. Time to metamorphosis
is critical for larval survival because larvae of amphibian
species such as R. pipiens, which normally complete metamor-
phosis in the first summer after egg laying, will likely die if they
do not fully metamorphose during that summer and are forced to
overwinter [25]. Additionally, because many amphibians lay
their eggs in temporary ponds to avoid predation by fish, failure
to complete metamorphosis before the pond dries could result in
increased crowding and competition or desiccation [34].This study was limited in that we were not able to begin the
study with ova, so many of the key morphogenic events were
completed before commencement of the study. Serotonin is
critical in very early development, and changes in the level of
serotonin may be particularly detrimental during cleavage,
gastrulation, neurulation, cardiac and craniofacial morphogen-
esis, and the establishment of normal left–right asymmetry
[16,35,36]. Therefore, exposure during all stages of develop-
ment, especially early development, may uncover more serious
consequences of chronic fluoxetine exposure.
The results of this study indicate that even environmentally
relevant concentrations of fluoxetine may delay the develop-
ment of tadpoles, thereby putting tadpoles at greater risk of
desiccation and overcrowding as temporal ponds dry, as well as
size-specific predation. Although not considered in this study,
added stressors, such as disease and habitat alterations, may act
synergistically with fluoxetine, as with other toxicants, to
amplify the effects of fluoxetine or cause additional unforeseen
consequences [25]. Moreover, considering the synergistic
effects of animal exposure to multiple drugs is important, since
fluoxetine is frequently found in company with other SSRIs, as
well as many other classes of drugs and contaminants [1–4]. In
fact, at least two studies have found fluoxetine, when combined
with other drugs or toxins, to have both lethal and sublethal
effects on phytoplankton and Daphnia magna [37,38]. Future
studies involving amphibian exposure to pharmaceuticals and
other aquatic contaminants could help illuminate the causes of
some of the massive declines in amphibian populations and
point us towards ways of averting further extinctions.
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